We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GT20029

News List

Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China prnasia
July 28, 2021
Kintor Pharmaceutical Limited announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne prnasia
July 14, 2021
Kintor Pharmaceutical Limited today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects.
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China prnasia
April 16, 2021
Kintor Pharmaceutical Limited announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (tincture/gel) for the treatment of acne and androgenetic alopecia.
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA prnasia
February 02, 2021
Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.